Jul 23, 2026 08:15AM
Jul 20, 2026 12:15PM
Jul 20, 2026 12:13PM
Jun 18, 2026 06:11AM
May 26, 2026 06:52AM
May 22, 2026 10:38AM
May 21, 2026 06:02AM Immix Biopharma reports 95% response rate in AL amyloidosis trial
May 11, 2026 04:14AM
Mar 31, 2026 04:25AM
Mar 30, 2026 08:47AM
Mar 30, 2026 06:42AM
Mar 27, 2026 11:40AM
Mar 27, 2026 06:45AM
Mar 27, 2026 04:08AM Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens After Q4 Result
Mar 25, 2026 04:44AM
Mar 9, 2026 03:29AM
Feb 9, 2026 05:26AM
Dec 10, 2025 08:25AM
Sep 18, 2025 01:30PM
Sep 12, 2025 06:44AM
Aug 6, 2025 12:31PM Immix Biopharma plans partnerships for other serious disease programs
Jul 11, 2025 09:36AM
Jul 8, 2025 06:51AM
Jul 7, 2025 09:35AM
Jun 4, 2025 06:47AM
Jun 3, 2025 02:56PM
May 23, 2025 09:06AM
May 22, 2025 04:05PM Immix Biopharma (IMMX) announces positive results for NXC-201
Feb 11, 2025 06:48AM
Feb 10, 2025 09:35AM
Jan 7, 2025 09:34AM
Jan 6, 2025 07:10AM
Dec 19, 2024 09:35AM
Dec 16, 2024 09:48AM
Dec 10, 2024 09:39AM Immix Biopharma (IMMX) Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Nov 25, 2024 09:32AM
Oct 3, 2024 07:03AM
Sep 19, 2024 09:31AM
Aug 28, 2024 09:32AM
Jun 10, 2024 08:33AM

436,138 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All